India Pharma Outlook Team | Monday, 13 October 2025
Samsung Biologics, a major global contract development and manufacturing organization (CDMO), has introduced ExellenS, a redesigned manufacturing framework that allows the standardization and accelerated working of its biomanufacturing operations across the globe.
The company aims with that project to raise the uniformity, the pace, and the expandability, giving biopharma clients quick technology transfers, fast-tracked approvals, and easy capacity upscaling.
ExellenS, being built on Samsung Biologics’ expertise in plant design, digitalization, and operational excellence, allows equipment, processes, and functional specifications to be standardized, meaning the utmost uniform precision will be achieved in all facilities. The framework upholds high-quality and predictable results, which leads to the strengthening of the company’s position as a pure-play CDMO.
"We can understand the necessity of the application of the production framework through the development and delivery of products on schedule along with manufacturing excellency due to the fact that we have such competences," said John Rim, President, and CEO of Samsung Biologics.
"One, it sets consistent project execution across our plants, and second, it provides us with the guidance for scalable and standardized operations as we are growing and diversifying in the CDMO landscape."
Also Read: Merck Unveils HIV Treatment, Prevention Results at EACS
With this structure, we included the four goals of the company - client satisfaction, operations, quality, and people expertise—in every facility, with its standardization, simplification and scalability.
Rim added, "With ExellenS, we can give our clients the assurance and adaptability they need to promote their therapies and bring hope to patients all over the globe."
The commitment of Samsung Biologics to accelerating patient access to life-saving therapies and enabling biopharmaceutical innovation is solidified by this introduction.
